DE-CSC
3.6.2021 15:02:13 CEST | Business Wire | Press release
CSC, the world’s leading provider of business, legal, tax, and digital brand services, is pleased to announce that it has acquired PEF Services LLC (PEF), a leading provider of technology-enabled fund administration services to private capital firms and their investors, including private equity, private debt, venture capital, and U.S.-based small business investment companies (SBICs).
This strategic acquisition greatly accelerates CSC’s fund services growth plans in the U.S., adding expertise and a robust technology platform to CSC’s increasingly sophisticated solutions. The deal underscores CSC’s commitment to the growing private capital fund administration market and builds upon CSC’s other recent expansion efforts in the U.S., Europe, and Asia.
“We’re very excited to welcome Anne Anquillare and the entire PEF team to CSC,” says CSC Executive Vice President John Hebert. “Their deep expertise in fund administration complements our existing capabilities, while their commitment to service excellence aligns well with our company culture.”
U.S.-based PEF was founded in 2002 to support the unique compliance and reporting needs of SBICs. As federally licensed entities, these alternative investment vehicles have requirements that other service firms struggle to meet. PEF’s success in managing these intricate requirements allowed it to expand easily to include all types of illiquid alternative asset firms, especially those with customized needs, which aligns nicely with CSC’s passion for complex structures. PEF’s deep understanding of the complexities and customer needs in the illiquid alternative asset class has resulted in its reputation for thought leadership. CSC’s acquisition of PEF Services furthers CSC’s unwavering commitment to alternative asset managers and their investors.
In addition to PEF’s client services team, CSC will now have access to PEF’s industry-leading ViewPoint ™ investor and general partner portal. Since its inception, PEF has been at the forefront of fund administration technology, providing their clients a mix of proprietary technologies and industry-standard platforms, resulting in a system that is powerful, flexible, and purpose-built for private capital fund financial reporting, investor communications, and data management.
Anne Anquillare, CFA, chief executive officer and president of PEF, joins CSC as the head of CSC U.S. Fund Services. Beth Manzi, CPA, chief operating officer of PEF, joins CSC to lead U.S. operations for fund administration. Oleg Yablonovskiy, managing director of CSC U.S. Fund Services, will move into a strategic role to drive synergies between the businesses. CSC values that PEF is a woman-led business, and these new roles reinforce CSC’s strong commitment to diversity and inclusion. PEF’s high-quality tenured team of professionals will join CSC immediately as part of the acquisition.
“As market requirements expanded, we searched for the perfect partner to enhance the exceptional fund administration services and technology solutions we provide,” says Anquillare. “CSC already has tremendous resources supporting private capital firms on a global scale and we will be a natural extension of those services. In turn, CSC recognized PEF’s reputation for having one of the most skilled and respected teams in the industry, leading-edge portal technology, and thought leadership in private capital. Both firms share a commitment in supporting private capital firms with excellent customer service, innovative technology, and investing in our people.”
About CSC
CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500®, nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com .
About PEF
PEF is the new standard in providing high-value, high-touch fund administration services and technology solutions that elevate operational performance to drive and support sustainable growth. Supported by senior professionals with extensive experience in alternative investments, PEF has a nearly 20-year track record of delivering cost-effective, best-in-class solutions to funds and general partnerships, including buyout, venture, emerging managers, real estate, debt, fund of funds, co-investment, SPVs and SBICs. Additionally, the firm focuses on meeting the unique administration and data needs of limited partners investing in illiquid alternative assets. PEF’s ViewPoint™ provides clients with a purpose-built portal that delivers greater visibility and real-time access to underlying investment performance data sourced directly from the official books and records of the fund. For more information, please visit pefservices.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
